Mechanism of Action
AICAR acts via intracellular conversion to ZMP, a direct AMPK activator.
AMPK Activation via ZMP
AICAR enters cells via adenosine transporters and is phosphorylated by adenosine kinase to AICAR-5-monophosphate (ZMP). ZMP mimics the elevated AMP:ATP ratio that occurs during exercise/energy stress, directly binding to the AMPK gamma subunit's allosteric AMP-binding site and activating the kinase. Unlike metformin which indirectly activates AMPK via Complex I inhibition, ZMP directly mimics the exercise-stress AMP signal.[1]Downstream Metabolic Consequences
AMPK activation drives: glucose uptake via GLUT4 translocation, fatty acid oxidation via ACC2 inhibition and CPT1 activation, mitochondrial biogenesis via PGC-1alpha, and autophagy via ULK1 phosphorylation. These collectively recreate many metabolic adaptations to endurance exercise.[2]Connection to MOTS-c Pathway
MOTS-c acts upstream by inhibiting the folate cycle enzyme MTHFD1, leading to AICAR accumulation as a metabolic consequence. AICAR and MOTS-c therefore converge on the same AMPK activation point through different upstream mechanisms.[3]Research Overview
Exercise Mimetic, Endurance Without Training
Most StudiedThe landmark 2008 Narkar et al. (Salk Institute) study showed AICAR alone increased running distance 44% in untrained mice via AMPK-driven fiber type shift and metabolic adaptation. Combined with GW501516 (PPARdelta agonist), the increase was 75%. These results established AICAR as the prototype metabolic "endurance drug" and led to WADA prohibition.[1]
Cardiac Ischemia Protection
Phase II ClinicalAICAR (Acadesine) was evaluated in Phase II/III cardiac surgery trials for ischemia-reperfusion protection. The ACES trial (N=2,059) showed 27% reduction in adverse cardiac events in high-risk patients undergoing CABG. Mechanism involves AMPK-mediated cardioprotection during ischemia.[4]
Insulin Sensitivity and Metabolic Disease
Strong EvidenceAMPK activation by AICAR improves insulin sensitivity independently of weight loss in animal models. GLUT4 translocation drives non-insulin-dependent glucose uptake. Relevant for type 2 diabetes and insulin resistance research.[2]
Calculate your AICAR dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Metabolic / endurance | 50–100 mg | Once daily (pre-exercise) | Subcutaneous |
| AMPK longevity stack | 50 mg AICAR + 5-10 mg MOTS-c | Morning fasted | Subcutaneous |
| Conservative start | 25–50 mg | Once daily | Subcutaneous |
Pre-exercise morning dosing. Fasted administration enhances AMPK activation. Start at low doses, AICAR potently activates AMPK and dose-response can be steep. Note: clinical IV doses (250-500 mg) are far higher than research SC protocols.
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
AICAR has Phase II/III cardiac surgery safety data at higher IV doses.
WADA: Prohibited as a metabolic modulator and gene expression activator (the "exercise in a pill" prohibition).
Hypoglycemia: AMPK-driven GLUT4 translocation can cause significant glucose lowering, especially in fasted state or with diabetes medications. Have fast-acting glucose available.
Cardiac dose context: Clinical ACES trial used IV doses of 140 mg/kg over 7 hours, far above typical research SC protocols. SC doses of 50-100 mg have a much more favorable safety profile.
No FDA approval: Not approved for any indication.
References
- [1]Narkar VA, et al. "AMPK and PPARdelta agonists are exercise mimetics." Cell. 2008;134(3):405-415.
- [2]Merrill GF, et al. "AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle." Am J Physiol. 1997;273(6 Pt 1):E1107-12.
- [3]Lee C, et al. "MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus." Bioessays. 2019;41(7):e1800249.
- [4]Newman MF, et al. "Acadesine and cardiovascular outcomes." J Thorac Cardiovasc Surg. 2009;138(3):619-628.